Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)

The National Institute of Allergy and Infectious Diseases (NIAID) seeks grant applications to conduct large‑scale implementation‑science research that accelerates the uptake, sustainment, and scale‑up of evidence‑based HIV prevention, treatment, and care interventions in U.S. communities heavily impacted by HIV. Projects may be single‑site, multi‑site, or comparative studies and may include an optional clinical‑trial component (R61/R33 mechanism). Up to ten awards are anticipated, with a total estimated funding pool of $7 million. Successful applicants will partner with local, state, and federal public‑health entities and must submit a Data Management and Sharing Plan, annual progress reports, and, if moving from the R61 to R33 phase, a transition package. • Target area: HIV implementation science in high‑impact U.S. communities. • Funding mechanism: R61 (phase I) → optional R33 (phase II) grant; up to 10 awards. • Total estimated award ceiling: $7 million (average ≈ $700 k per award). • Expected project length: up to 7 years (R61 ≈ 2 years, R33 up to 5 years). • Eligible entities: wide range including state/local governments, nonprofits (501(c)(3) and others), tribal governments, for‑profit firms, academic institutions, and foreign entities. • Required deliverables: implementation‑science research plan, DMS plan, annual RPPRs, transition package for R33. • Key contacts: Rebecca Mandt, Ph.D. (program officer) and NIAID scientific/financial contacts.